Reporting rates of rhabdomyolysis with statins to the FDA

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2002年 / 898卷 / 1期
关键词：
Statin; Digoxin; Simvastatin; Atorvastatin; Pravastatin;
D O I：
10.2165/00128415-200208980-00008
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4 / 4
相关论文
共 50 条
  • [21] Rhabdomyolysis of Multifactorial Origin in Schizophrenia Antipsychotics, Statins, Trauma
    Botillo-Martin, Carlota
    Gonzalez-Pablos, Emilio
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2018, 38 (03) : 261 - 263
  • [22] Cardiac adverse events associated with statins in myocardial infarction patients: a pharmacovigilance analysis of the FDA Adverse Event Reporting System
    Deng, Chuanhuan
    Lin, Xiaofang
    Ni, Dan
    Yuan, Ludong
    Li, Jing
    Liu, Yuxuan
    Liang, Pengfei
    Jiang, Bimei
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2025, 47 (01) : 46 - 52
  • [23] Statins-induced myalgia and rhabdomyolysis: Characterization of muscle contraction
    Guis, S
    Bendahan, D
    Figarella-Branger, D
    Mattei, J
    Kozak-Ribbens, G
    Nicoli, F
    Legeron, P
    Pellissier, J
    Cozzone, PJ
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 74 - 74
  • [24] Rhabdomyolysis in prostate cancer - Caution in prescribing cyproterone acetate with statins
    Ahamed, E
    Bissett, D
    CLINICAL ONCOLOGY, 2004, 16 (08) : 528 - 529
  • [25] Statins for primary prevention and rhabdomyolysis: A nationwide cohort study in France
    Coste, Joel
    Billionnet, Cecile
    Rudnichi, Annie
    Pouchot, Jacques
    Dray-Spira, Rosemary
    Giral, Philippe
    Zureik, Mahmoud
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (05) : 512 - 521
  • [26] An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system
    Colman, Eric
    Szarfman, Ana
    PharmD, Jo Wyeth
    Mosholder, Andrew
    Jillapalli, Devanand
    Levine, Jonathan
    Avigan, Mark
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (11) : 1068 - 1076
  • [27] A Pharmacoepidemiological Network Model for Drug Safety Surveillance Statins and Rhabdomyolysis
    Reis, Ben Y.
    Olson, Karen L.
    Tian, Lu
    Bohn, Rhonda L.
    Brownstein, John S.
    Park, Peter J.
    Cziraky, Mark J.
    Wilson, Marcus D.
    Mandl, Kenneth D.
    DRUG SAFETY, 2012, 35 (05) : 395 - 406
  • [28] Rhabdomyolysis - Has many causes, including statins, and may be fatal
    Lane, R
    Phillips, M
    BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7407): : 115 - 116
  • [29] Data Mining of the FDA Adverse Event Reporting System and Animal Experiments for Assessment of Rhabdomyolysis Risk Associated with Lipid-lowering Drugs
    Kobuchi, Shinji
    Sugiyama, Daisuke
    Iima, Anna
    Obuchi, Ami
    Osaka, Ayumi
    Doi, Ayana
    Ueta, Hikaru
    Yokoyama, Satoshi
    Hosomi, Kouichi
    Takada, Mitsutaka
    Sakaeda, Toshiyuki
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2025, 22 (07): : 1485 - 1492
  • [30] FDA to oversee reporting of clinical trials
    Mark Ratner
    Nature Biotechnology, 2012, 30 : 1163 - 1163
12345